InvestorsObserver
×
News Home

Should You Buy Pharvaris NV (PHVS) Stock After it Has Risen 12.56% in a Week?

Tuesday, August 15, 2023 11:09 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Pharvaris NV (PHVS) Stock After it Has Risen 12.56% in a Week?

Pharvaris NV (PHVS) stock is higher by 12.56% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,neutral
Pharvaris NV has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on PHVS!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With PHVS Stock Today?

Pharvaris NV (PHVS) stock has risen 10.48% while the S&P 500 is lower by -0.82% as of 11:08 AM on Tuesday, Aug 15. PHVS is higher by $1.93 from the previous closing price of $18.42 on volume of 140,165 shares. Over the past year the S&P 500 is higher by 3.63% while PHVS is higher by 2.78%. PHVS lost -$2.85 per share in the over the last 12 months. To screen for more stocks like Pharvaris NV click here.

More About Pharvaris NV

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Click Here to get the full Stock Report for Pharvaris NV stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App